Cancer Metabolism as a Therapeutic Target and Review of Interventions

Nutrients, Journal Year: 2023, Volume and Issue: 15(19), P. 4245 - 4245

Published: Oct. 1, 2023

Cancer is amenable to low-cost treatments, given that it has a significant metabolic component, which can be affected through diet and lifestyle change at minimal cost. The Warburg hypothesis states cancer cells have an altered cell metabolism towards anaerobic glycolysis. Given this reprogramming in cells, possible target cancers metabolically by depriving them of glucose. In addition dietary modifications work on tumors metabolically, there are panoply nutritional supplements repurposed drugs associated with prevention better treatment outcomes. These interventions their evidentiary basis covered the latter half review guide future treatment.

Language: Английский

---

Recent Advances in the Anticancer Applications of Benzimidazole Derivatives

ChemistrySelect, Journal Year: 2023, Volume and Issue: 8(35)

Published: Sept. 15, 2023

Abstract Cancer, one of the most deadly diseases worldwide, is still a crucial challenge to human well‐being. Hence, design and development modern protocols cure diverse kinds cancer seem highly necessary. On other hand, benzimidazole, as an essential pharmacophore, exhibits various biological therapeutic potency. This compound well‐known for its pharmaceutical features, including antifungal, antiviral, antibacterial, anticancer activities. Therefore, benzimidazole derivatives have played role due their outstanding capability, apoptotic effect, inhibitory potential. In recent decades, numerous drug types research been concentrated on finding new practical strategies employing benzimidazole‐based compounds. review focuses latest advancements methodologies exploiting benzimidazole‐bearing compounds treatment varied sorts cancer, considering mechanism function against cell lines.

Language: Английский

---

Repurposing Therapeutic Drugs Complexed to Vanadium in Cancer

Pharmaceuticals, Journal Year: 2023, Volume and Issue: 17(1), P. 12 - 12

Published: Dec. 21, 2023

Repurposing drugs by uncovering new indications for approved accelerates the process of establishing treatments and reduces high costs drug discovery development. Metal complexes with clinically allow further opportunities in cancer therapy—many vanadium compounds have previously shown antitumor effects, which makes a suitable metal to complex therapeutic drugs, potentially improving their efficacy treatment. In this review, covering last 25 years research field, we identified non-oncology-approved as ligands obtain different complexes. Metformin-decavanadate, vanadium-bisphosphonates, vanadyl(IV) non-steroidal anti-inflammatory cetirizine imidazole-based oxidovanadium(IV) complexes, each has parent known medicinal properties indications, all showed potential novel anticancer treatments. Nevertheless, precise mechanisms action these against are still not fully understood.

Language: Английский

---

Drug Repurposing in Oncology: A Systematic Review of Randomized Controlled Clinical Trials

Cancers, Journal Year: 2023, Volume and Issue: 15(11), P. 2972 - 2972

Published: May 30, 2023

Quality pharmacological treatment can improve survival in many types of cancer. Drug repurposing offers advantages comparison with traditional drug development procedures, reducing time and risk. This systematic review identified the most recent randomized controlled clinical trials that focus on oncology. We found only a few were placebo-controlled or standard-of-care-alone-controlled. Metformin has been studied for potential use various cancer, including prostate, lung, pancreatic Other studies assessed possible antiparasitic agent mebendazole colorectal cancer propranolol multiple myeloma or, when combined etodolac, breast able to identify study known antineoplastics other non-oncological conditions, such as imatinib severe coronavirus disease 2019 protocol aiming assess leuprolide Alzheimer’s disease. Major limitations these small sample size, high heterogeneity participants regarding stage neoplastic disease, lack accounting multimorbidity baseline characteristics. possibilities oncology must be carefully examined well-designed trials, considering factors could influence prognosis.

Language: Английский

---

In silico Repurposing of FDA-Approved Drugs as Multi-target Inhibitors of Glioblastoma

Scientific African, Journal Year: 2025, Volume and Issue: unknown, P. e02582 - e02582

Published: Feb. 1, 2025

Language: Английский

---

Benzimidazole‐Based Anthelmintic Drugs: Synthetic Strategy, Pharmacological Insights, and SAR Analysis

ChemistrySelect, Journal Year: 2025, Volume and Issue: 10(10)

Published: March 1, 2025

Abstract Helminth diseases from parasitic worms create major problems worldwide in human health and farming operations. Benzimidazole derivatives bind specifically to β‐tubulin serve as essential components worm treatment medications. Drug researchers need new approaches because current treatments are becoming less effective. This review delves into the pharmacological properties, mechanisms of action, structure–activity relationships (SAR) benzimidazole derivatives, with a focus on synthetic modifications such lipophilic substitutions enhance membrane permeability carbamate moiety optimization for improved binding affinity. The presents latest drug resistance strategies, which include delivery systems through nanotechnology resistance‐overcoming agent combinations. Scientists found that absorption safety patterns albendazole, mebendazole, triclabendazole work well parasite control across different locations. study investigates using modern screening methods artificial intelligence discover against infections. Our discusses developments improve antiparasitic medicine handling increasing infection rates.

Language: Английский

---

Mebendazole induces apoptosis and inhibits migration via the reactive oxygen species-mediated STAT3 signaling downregulation in non-small cell lung cancer

Journal of Thoracic Disease, Journal Year: 2024, Volume and Issue: 16(2), P. 1412 - 1423

Published: Feb. 1, 2024

Background: The incidence and mortality of non-small cell lung cancer (NSCLC) are extremely high. Previous research has confirmed that the signal transducer activator transcription 3 (STAT3) protein critically participate in tumorigenesis NSCLC. Mebendazole (MBZ) exerts a larger number pharmacological activities anticancer effects cancer, but its mechanism action remains unclear. This study thus aimed to clarify impacts MBZ on NSCLC cell. Methods: Cell proliferation, migration, apoptosis were investigated via counting kit 8 (CCK-8) assay, Transwell colony formation wound-healing flow cytometry. Reactive oxygen species (ROS) detected with multifunctional microplate reader. Markers migration Western blotting. transcriptional activity STAT3 was luciferase assay. ROS scavenger N-acetylcysteine (NAC) used determine effect ROS-regulated inactivation apoptosis. A xenograft model constructed vivo investigate role tumor growth. Results: findings demonstrated inhibited proliferation while promoting through triggering generation. In addition, Janus kinase 2 (JAK2)-STAT3 signaling pathway abrogated treatment MBZ. NAC could distinctly weaken MBZ-induced inactivation. Moreover, growth vivo. Conclusions: summary, viability by inducing ROS-JAK2-STAT3 pathway. These data provide theoretical basis for use treating

Language: Английский

---

Synthesis, Cytotoxic Activity, Antiquorum Sensing Effect, Docking and Md Simulation of Novel 1,3‐Disubstituted 2‐Mercapto‐1H‐Benzo[D]Imidazolium Chlorides

Journal of Biochemical and Molecular Toxicology, Journal Year: 2025, Volume and Issue: 39(4)

Published: April 1, 2025

ABSTRACT A series of benzimidazolium chlorides ( 2a‐c ) and their corresponding 2‐mercapto derivatives 3a‐c were proficiently synthesized analyzed by NMR LC‐MS spectra. The in vitro cytotoxic assay demonstrated that some compounds active on the cancer cell lines. binding potential most three to topoisomerase II alpha (topo2α) was explored unveil possible mode action for activity. examined through molecular docking. stability compound‐enzyme complexes from docking investigated dynamics (MD) simulation. study revealed showed ability bind enzyme. However, strength weaker than standard drug, doxorubicin. MD simulation analysis 3a 3b gave relatively stable with enzyme thus they would remain inside pocket during period. Furthermore, pharmacokinetic properties computed silico . computation disclosed all exhibited drug‐like properties. It is worth mentioning them found be nontoxic. In furtherance, inhibitory effect quorum sensing system inspected using biomonitor strains Chromobacterium violaceum 026, Chromobacterium. VIR07 Pseudomonas aeruginosa PAO1. this regard, we focused appraisal virulence factors, including pyocyanin, elastase, biofilm formation are created P. PAO1 as source infectious diseases. As a result, it determined displayed statistically significant inhibition effects, highest activity observed elastase production an rate 84–86%.

Language: Английский

---

Repurposing of Mebendazole as an Anticancer Agent: A Review

Research Journal of Pharmacy and Technology, Journal Year: 2025, Volume and Issue: unknown, P. 1619 - 1624

Published: April 12, 2025

Cancer is global health problem causing death around the world. Traditional chemotherapy drugs have significant side effects and recent research has proven that Food Drug Administration authorized medication mebendazole shows anticancer effects. The present review summarizes mebendazole, as potential agent. Mebendazole effective against brain, melanoma, ovariancancer, meningioma cancer, prostate pancreatic, lung, breast colorectal cancer. its through programmed cell death, halt in division process, prevention of angiogenesis. It can also act on cancer related mechanisms like, MEK/ERK, AP1, STAT1/2, ELK1/SRF, MYC/MAX. According to pharmacokinetic profile it quick first pass metabolism with poor oral bioavailability. treatment, either by itself or combined other medications, led a notable decrease progression metastatic disease, improvement survival, reduction cessation tumor growth. properties variety types, shown numerous preclinical investigations clinical trials.

Language: Английский

---

The Neurodevelopmental and Molecular Landscape of Medulloblastoma Subgroups: Current Targets and the Potential for Combined Therapies

Cancers, Journal Year: 2023, Volume and Issue: 15(15), P. 3889 - 3889

Published: July 30, 2023

Medulloblastoma is the most common malignant pediatric brain tumor and associated with significant morbidity mortality in population. Despite use of multiple therapeutic approaches consisting surgical resection, craniospinal irradiation, multiagent chemotherapy, prognosis many patients medulloblastoma remains dismal. Additionally, high doses radiation chemotherapeutic agents used are short- long-term complications adverse effects, notably neurocognitive delay. Hence, there an urgent need for development clinical integration targeted treatment regimens greater efficacy superior safety profiles. Since adoption molecular-based classification into wingless (WNT) activated, sonic hedgehog (SHH) group 3, 4, research efforts have been directed towards unraveling genetic, epigenetic, transcriptomic, proteomic profiles each subtype. This review aims to delineate progress that has made characterizing neurodevelopmental molecular features It further delves implications these characteristics on subgroup-specific agents. Furthermore, it highlights potential future avenues combining or strategies order obtain augmented effects evade resistance tumors.

Language: Английский

---